medigraphic.com
ISSN 2520-9078 (Electronic)

2013, Number 2

<< Back Next >>

Revista de Ciencias Médicas de la Habana 2013; 19 (2)

Misoprostol in two forms of administration for cervical dilatation in instrumented abortion

García BLG, Alonso SM, Concepción PE

Language: Spanish
References: 20
Page:
PDF size: 76.06 Kb.


ABSTRACT

Introduction: misoprostol is an extremely useful product to be used as abortive drug, it has a high margin of safety when prescribed at adequate doses and with a proper medical supervision.
Objective: to evaluate the efficacy of misoprostol in the dilation of the cervix in instrumented abortion in pregnant women up to 9 weeks.
Methods: it was conducted an experimental study, between January and December 2011, at "Ivan Portuondo" General Teaching Hospital of San Antonio de los Baños municipality, Artemisa province, which compares two forms of administration of 400 mcg of misoprostol. The universe consisted of a total of 620 patients, of which 224 formed the sample.
Results: 113 patients were vaginally treated and 111 sublingually, 202 cases had an effective dilatation and 22 cases behaved ineffectively. In more than 2/3 parts of the cases, the time required for termination was normal, followed by those prolonged to 16.1% and finally, those who had a short surgical time with 11.6 %. Side effects that occurred more frequently were fever and chills in the case of the sublingual administration over 50%. Conclusions: prior administration of 400 mcg of misoprostol in instrumented abortion, proved to be more effective for cervical dilation when placed vaginally in contrast to sublingually.


REFERENCES

  1. Progresos de obstetricia y ginecología. Protocolo asistencial en obstetricia de la SEGO. El sevier [Internet]. 2002 Jul [citado 20 Ene 2011];45(7). Disponible en: http://zl.elsevier.es/es/revista/progresos-obstetricia-ginecologia-151/protocolosasistenciales- ginecologia-obstetricia-13035208-protocolos-sego-2002

  2. Carbonell JL, Varela L, Velazco A, Cabezas E, Tanda R, Sánchez C. Vaginal misoprostol for late first trimester abortion. Contraception [Internet]. 1998 May [cited 2010 Jan 15];57(5). Available from:http://www.ncbi.nlm.nih.gov/pubmed/9673840

  3. Has R, Batukan C, Ermis H, Cevher E, Araman A, Kılıç G [et al]. Comparison of 25 and 50 μg vaginally administered misoprostol for preinduction of cervical ripening and labor Induction. Gynecol Obstet Invest [Internet]. 2002 Jan [cited 2010 Jan 15];53(1). Disponible en: http://www.karger.com/Article/Fulltext/49405

  4. Porras-Zamora C, Porras O. Vademecum. Acta pediátr Costarric [Internet]. 2008 Ene [citado 15 Jun 2011];20(2). Disponible en: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409- 00902008000200008&lng=es.

  5. Schonhofer PS. Misuse of misoprostol as an abortifacient may induce malformations. Lancet 1991 Jun;337(8756):1534.

  6. MacKenzie WE. Misoprostol and the politics of fear. Lancet [Internet]. 2001 Abr [cited 2010 Jan 15];357(9264). Available from: http://www.thelancet.com/journals/lancet/article/PIIS01406736%2800%29044 45-7/fulltex

  7. Singh K, Fong YF, Prasad RN, Dong F. Randomized trial to determine optimal dose of vaginal misoprostol for preabortion cervical priming. Obstet Gynecol [Internet]. 1998 Nov [cited 2010 Jan 15];92(5). Available from:http://www.ncbi.nlm.nih.gov/pubmed/9794671

  8. Marcisz C, Jonderko G, Gina R, Szkliniarz J. Effects of misoprostol, a synthetic equivalent of prostaglandin E1 on bronchodilation in bronchial spasm. Pol Tyg Lek [Internet]. 1992 Aug [cited 2010 Jan 15];47(34-35). Available from:http://www.ncbi.nlm.nih.gov/pubmed/1488359

  9. Ministerio de Salud Pública y Asistencia Social. Guía para la atención integral de la hemorragia del primer y segundo trimestre y del post-aborto y sus complicaciones. 1ra ed. Guatemala: Ciencias Médicas; 2011.

  10. Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik F [et al]. Early termination of pregnancy with mifepristone (RU 486) and the orally active prosta-glandin misoprostol. N Engl J Med [Internet]. 1993 [cited 2010 Jan 15];328. Available from: http://www.nejm.org/doi/full/10.1056/NEJM199305273282101

  11. Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception [Internet]. 1996 Jun [cited 2010 Jan 15];53(6). Available from:http://www.contraceptionjournal.org/article/0010-7824%2896%2900080- 7/abstract

  12. Muzonzini G, Hofmeyr GJ. Misoprostol oral o sublingual para maduración cervical e inducción del trabajo de parto. Biblioteca Cochrane Plus [Internet]. 2013 [citado 20 Mar 2013];5. Disponible en: http://www.updatesoftware. com/BCP/BCPGetDocument.asp?DocumentID=CD004221

  13. Say L, Kulier R, Gülmezoglu M, Campana A. Métodos médicos versus métodos quirúrgicos para la interrupción del embarazo en el primer trimestre. Biblioteca Cochrane Plus [Internet]. 2013 [citado 20 Mar 2013];5. Disponible en:http://www.updatesoftware. com/BCP/BCPGetDocument.asp?DocumentID=CD003037

  14. Carbonell JL, Varela L. Vaginal misoprotol for abortion at 10-13 weeks off gestation. Eur J Contracept Reprod Health Care [Internet]. 2009 Mar [cited 2011 Jan 15];4(1). Available from: http://www.ncbi.nlm.nih.gov/pubmed/10367194

  15. Gippini I, Díaz de Terán E, Cristóbal I, Coronado P. Análisis del valor del misoprostol en el tratamiento del aborto diferido. Prog Obstet Ginecol [Internet]. 2011 [citado 20 Ene 2012]. Disponible en:http://www.elsevier.es/sites/default/files/elsevier/eop/S0304- 5013(11)00445-6.pdf

  16. Boletín de la SEFH. Misoprostol para la interrupción del embarazo: comparación de cuatro regímenes. Sociedad Española de Farmacia Hospitalaria. Lancet [Internet] 2007. [citado 20 Marzo 2011];369. Disponible en:http://www.sefh.es/sefhboletin/vernoticiaboletin.php?id=3019

  17. Carbonell JL, Varela L. Vaginal misoprostol for late first trimester abortion. Contraception. 1998; 57:329 -33.

  18. Rodríguez A, Velasco A, Gallego J. Empleo de 800 μg de misoprostol para la interrupción de embarazos hasta 9 semanas. Rev Cubana Obstet Ginecol [Internet]. 2007 [citado 20 Mar 2011];30(3). Disponible en:http://www.bvs.sld.cu/revistas/gin/vol30_3_04/gin02304.htm

  19. Echeverría LE, Quiroz NE, Rozas A. JC, Rocha O. MM, Hinrichs O. C, Jeréz M [et al]. Cinco años de experiencia con misoprostol intravaginal para la inducción de parto. Uso de una nueva presentación farmacéutica en supositorios. Rev Chil Obstet Ginecol [Internet]. 2002 [citado 15 Jul 2012];67(2). Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717- 75262002000200008&lng=es.

  20. Nápoles Méndez D. Uso de prostaglandinas en Ginecobstetricia. Hospital Provincial Docente “Dr. Antonio Luaces Iraola” de Ciego de Ávila. Cómo se asegura la calidad de los ensayos clínicos en el centro nacional coordinador de ensayos clínicos Centro Nacional Coordinador de Ensayos Clínicos. Medisan [Internet]. 2006 [citado 15 Jul 2012];9(2). Disponible en: http://bvs.sld.cu/revistas/san/vol9_2_05/san01205.htm.




2020     |     www.medigraphic.com